Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ANIK

ANIK - Anika Therapeutics Inc Stock Price, Fair Value and News

26.32USD+0.35 (+1.35%)Market Closed

Market Summary

ANIK
USD26.32+0.35
Market Closed
1.35%

ANIK Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

ANIK Stock Price

View Fullscreen

ANIK RSI Chart

ANIK Valuation

Market Cap

385.1M

Price/Earnings (Trailing)

-5.01

Price/Sales (Trailing)

2.28

EV/EBITDA

-4.44

Price/Free Cashflow

-92.97

ANIK Price/Sales (Trailing)

ANIK Profitability

EBT Margin

-45.96%

Return on Equity

-36.84%

Return on Assets

-29.13%

Free Cashflow Yield

-1.08%

ANIK Fundamentals

ANIK Revenue

Revenue (TTM)

169.3M

Rev. Growth (Yr)

6.85%

Rev. Growth (Qtr)

-5.7%

ANIK Earnings

Earnings (TTM)

-76.8M

Earnings Growth (Yr)

56.39%

Earnings Growth (Qtr)

92.83%

Breaking Down ANIK Revenue

52 Week Range

16.5427.37
(Low)(High)

Last 7 days

-1.0%

Last 30 days

1.5%

Last 90 days

2.1%

Trailing 12 Months

-3.5%

How does ANIK drawdown profile look like?

ANIK Financial Health

Current Ratio

5.59

Debt/Equity

0.12

Debt/Cashflow

0.07

ANIK Investor Care

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

-5.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024169.3M000
2023157.5M162.1M163.3M166.7M
2022150.2M151.7M152.4M156.2M
2021129.4M136.8M144.7M147.8M
2020125.3M125.5M127.5M130.5M
2019109.0M108.9M111.8M114.6M
2018111.3M108.4M108.0M105.6M
2017104.5M111.4M112.8M113.4M
201699.8M103.4M105.5M103.4M
201587.1M83.7M85.4M93.0M
201493.8M99.3M103.6M105.6M
201372.2M73.4M76.4M75.1M
201267.4M70.9M67.2M71.4M
201154.8M56.5M61.1M64.8M
2010045.3M50.4M55.6M
200900040.1M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Anika Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
capper joseph h
acquired
-
-
468
-
Jun 03, 2024
jellison william r
acquired
-
-
468
-
Mar 11, 2024
nunes anne
sold (taxes)
-44,000
25.5818
-1,720
svp, chief operations officer
Mar 11, 2024
nunes anne
acquired
-
-
5,856
svp, chief operations officer
Mar 11, 2024
colleran david
sold (taxes)
-126,306
25.5887
-4,936
evp, general counsel, corp sec
Mar 11, 2024
colleran david
acquired
-
-
16,809
evp, general counsel, corp sec
Mar 11, 2024
levitz michael l
sold (taxes)
-144,284
25.5913
-5,638
evp, cfo, treasurer
Mar 11, 2024
levitz michael l
acquired
-
-
19,201
evp, cfo, treasurer
Mar 11, 2024
blanchard cheryl r
sold (taxes)
-716,629
25.6122
-27,980
president, ceo, director
Mar 11, 2024
blanchard cheryl r
acquired
-
-
64,480
president, ceo, director

1–10 of 50

Which funds bought or sold ANIK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 28, 2024
Boston Partners
new
-
732,840
732,840
-%
May 16, 2024
COMERICA BANK
unchanged
-
247
2,286
-%
May 16, 2024
Virtus Investment Advisers, Inc.
unchanged
-
124,887
1,157,710
0.83%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.9
-17,199
37,389
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-45.92
-147,710
227,381
-%
May 15, 2024
Squarepoint Ops LLC
reduced
-10.41
5,552
1,332,410
-%
May 15, 2024
DEUTSCHE BANK AG\
added
0.94
244,391
2,103,780
-%
May 15, 2024
STATE STREET CORP
added
2.08
1,010,220
8,013,090
-%
May 15, 2024
Tudor Investment Corp Et Al
added
47.97
363,574
915,594
0.01%
May 15, 2024
WELLINGTON MANAGEMENT GROUP LLP
new
-
947,446
947,446
-%

1–10 of 48

Are Funds Buying or Selling ANIK?

Are funds buying ANIK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANIK
No. of Funds

Unveiling Anika Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 30, 2024
caligan partners lp
9.7%
1,435,993
SC 13D/A
Apr 05, 2024
blackrock inc.
10.7%
1,561,112
SC 13G/A
Mar 06, 2024
caligan partners lp
9.7%
1,423,493
SC 13D/A
Feb 13, 2024
vanguard group inc
5.22%
764,045
SC 13G/A
Feb 09, 2024
dimensional fund advisors lp
5.6%
821,452
SC 13G/A
Feb 09, 2024
trigran investments, inc.
14.6%
2,139,054
SC 13G/A
Jan 24, 2024
blackrock inc.
9.5%
1,383,877
SC 13G/A
Jan 22, 2024
state street corp
2.11%
309,041
SC 13G/A
Oct 06, 2023
blackrock inc.
9.7%
1,416,135
SC 13G/A
Sep 11, 2023
caligan partners lp
7.4%
1,081,360
SC 13D/A

Recent SEC filings of Anika Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
ARS
ARS
Jun 11, 2024
DEF 14A
DEF 14A
Jun 05, 2024
3
Insider Trading
Jun 05, 2024
3
Insider Trading
Jun 05, 2024
3
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
May 31, 2024
S-8
Employee Benefits Plan
May 30, 2024
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to Anika Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.56% 0.17%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.30% -8.44%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.39% -15.83%
44.18
5.21
5.72% 46.72%
17.2B
14.9B
-4.28% -22.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.42% 26.61%
30.89
2.73
6.16% 35.06%
8.5B
12.4B
-8.96% -11.44%
21.87
0.68
-0.93% -18.83%
8.0B
2.6B
-4.13% -24.00%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-5.09% -29.87%
-58.05
1.41
0.23% 90.80%
3.4B
387.1M
-0.21% 32.29%
-215.63
8.87
30.82% 65.57%
2.0B
6.6B
-10.10% -15.73%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
18.01% 16.23%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
1.48% -3.53%
-5.01
2.28
7.49% -244.90%
249.1M
324.0M
0.65% -42.87%
-1.3
0.77
-3.19% -337.41%
50.6M
50.5M
3.55% -78.84%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-17.65% -79.41%
-0.15
0.48
5.77% 8.23%

Anika Therapeutics Inc News

Latest updates
MarketBeat11 Jun 202406:56 pm
Yahoo Movies UK27 May 202403:07 am
StockNews.com01 May 202407:00 am

Anika Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-5.7%40,523,00042,971,00041,465,00044,302,00037,924,00039,622,00040,264,00039,657,00036,693,00035,821,00039,536,00038,145,00034,292,00032,688,00031,694,00030,678,00035,397,00029,772,00029,697,00030,418,00024,723,000
Gross Profit-6.5%24,628,00026,329,00024,944,00028,972,00022,843,00024,131,00022,779,00024,862,00021,804,00018,134,00023,023,00020,812,00020,974,00016,745,00017,343,00013,742,00021,197,00021,123,00023,746,00023,582,00017,412,000
Costs and Expenses-67.1%29,691,00090,110,00032,618,00032,603,00035,396,00030,798,00028,577,00028,243,00025,358,00027,257,00021,723,00011,632,00019,716,00034,697,00025,270,00023,278,00014,103,000-3,777,00017,648,00018,503,00019,241,000
  S&GA Expenses5.9%21,527,00020,335,00024,827,00023,689,00026,996,00023,049,00021,276,00021,268,00019,201,00020,432,00017,500,00017,989,00018,175,00015,179,00015,903,00014,550,00014,431,00012,237,0007,539,0007,502,0007,672,000
  R&D Expenses7.6%8,164,0007,585,0007,791,0008,914,0008,400,0007,749,0007,301,0006,975,0006,157,0006,000,0007,673,0007,293,0006,361,0007,632,0005,217,0004,532,0006,050,0004,084,0004,158,0004,165,0004,258,000
EBITDA Margin11.1%-0.42-0.47-0.13-0.13-0.13-0.08-0.10-0.050.030.060.00-0.10---------
Income Taxes124.1%43,000-178,500-463,000-300,000-1,700,000-1,472,500-1,187,000-442,000-800,000-3,404,000694,0002,600,000-1,600,000-2,501,500-1,700,000-2,000,0001,580,0001,126,0003,331,0003,000,0001,473,000
Earnings Before Taxes92.9%-4,471,000-63,204,000-7,039,000-3,070,000-12,014,000-6,391,000-5,362,000-3,285,000-3,708,000-9,170,0001,252,0009,130,0001,215,000-18,137,000-8,155,000-9,705,0007,373,0005,162,00012,531,00012,448,0005,980,000
EBT Margin10.2%-0.46-0.51-0.17-0.17-0.17-0.12-0.14-0.10-0.020.02-0.05-0.12---------
Net Income92.8%-4,514,000-63,000,000-6,576,000-2,741,000-10,350,000-4,908,000-4,175,000-2,843,000-2,933,000-5,793,000558,0006,531,0002,838,000-15,657,000-6,411,000-7,708,0005,793,0004,051,0009,200,0009,435,0004,507,000
Net Income Margin8.5%-0.45-0.50-0.15-0.14-0.14-0.10-0.10-0.07-0.010.03-0.04-0.09---------
Free Cashflow-207.6%-1,934,0001,798,0005,744,000-9,750,000-5,007,000-2,048,0001,018,0001,148,000-3,195,0003,345,000778,0001,979,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.5%264271328329339349348354342348353363362366416441399331320287307
  Current Assets-2.7%159163157152160170168168165169166178173177202221161234224190210
    Cash Equivalents-5.8%69.0073.0071.0065.0080.0086.0088.0091.0090.0094.0091.0097.0095.0096.0010411766.0015710369.0096.00
  Inventory6.5%49.0046.0044.0043.0041.0040.0037.0035.0035.0036.0035.0043.0043.0046.0048.0046.0043.0022.0025.0023.0023.00
  Net PPE-0.3%46.0046.0046.0048.0049.0048.0047.0048.0048.0048.0049.0050.0049.0051.0052.0053.0054.0051.0052.0053.0053.00
  Goodwill-2.2%7.008.007.007.007.007.007.007.008.008.008.008.008.008.0032.0034.0034.008.007.008.008.00
  Current Liabilities-8.4%28.0031.0028.0023.0029.0028.0026.0029.0027.0030.0029.0041.0047.0037.0031.0028.0026.0016.0011.0010.0012.00
  Long Term Debt---------------25.0050.00-----
    LT Debt, Non Current---------------25.0050.00-----
Shareholder's Equity-1.8%209212270274278286285286286287290287277272284288294288282251269
  Retained Earnings-3.5%124128191198200211216220223226231231224221237244251245241232223
  Additional Paid-In Capital1.3%91.0090.0086.0082.0083.0081.0077.0073.0069.0067.0064.0061.0057.0055.0053.0051.0048.0049.0046.0024.0052.00
Shares Outstanding1.1%15.0015.0015.0015.0015.0015.0015.0015.0014.0014.0014.0014.00---------
Float----370---322---620---531---570-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-103.5%-1263,6386,485-8,293-3,6184812,7093,088-1,8694,4722,0624,294-2,4312,5875,8653,5681,04513,02210,0515,4708,462
  Share Based Compensation-5.9%3,5903,8153,5614,1503,7173,8133,8764,0812,5453,1662,8632,7972,2591,4331,9202,240-2071,9471,3111,4431,386
Cashflow From Investing1.7%-1,808-1,840-741-1,457-1,389-2,529-1,691-1,940-1,326-1,240-1,295-2,3171,73416,8096,729-2,299-92,50341,0242,100-1,516-1,917
Cashflow From Financing-764.6%-2,273342-110-4,943-1,613667-4,611-46.00-86260.00-6,982594-451-28,112-25,17949,658-14127821,699-30,000-119
  Buy Backs----5,050---------------30,000-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ANIK Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue$ 40,523$ 37,924
Cost of revenue15,89515,081
Gross Profit24,62822,843
Operating Expenses:  
Research and development8,1648,400
Selling, general and administrative21,52726,996
Total operating expenses29,69135,396
Loss from operations(5,063)(12,553)
Interest and other income (expense), net592539
Loss before income taxes(4,471)(12,014)
Provision for (benefit from) income taxes43(1,664)
Net loss$ (4,514)$ (10,350)
Net loss per share:  
Basic (in dollars per share)$ (0.31)$ (0.71)
Diluted (in dollars per share)$ (0.31)$ (0.71)
Weighted average common shares outstanding:  
Basic (in shares)14,69814,653
Diluted (in shares)14,69814,653
Net loss$ (4,514)$ (10,350)
Foreign currency translation adjustment(372)272
Comprehensive loss$ (4,886)$ (10,078)

ANIK Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 68,629$ 72,867
Accounts receivable, net32,07735,961
Inventories, net49,40846,386
Prepaid expenses and other current assets8,8488,095
Total current assets158,962163,309
Property and equipment, net46,05746,198
Right-of-use assets28,18128,767
Other long-term assets17,57118,672
Deferred tax assets1,2731,489
Intangible assets, net4,2974,626
Goodwill7,4037,571
Total assets263,744270,632
Current liabilities:10,0229,860
Accrued expenses and other current liabilities18,43821,199
Total current liabilities28,46031,059
Other long-term liabilities404404
Lease liabilities26,34426,904
Commitments and contingencies (Note 9) 
Common stock, $0.01 par value; 90,000 shares authorized, 15,009 issued and 14,821 outstanding and 14,848 issued and 14,660 outstanding at March 31, 2024 and December 31, 2023, respectively148147
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively00
Additional paid-in-capital91,16590,009
Accumulated other comprehensive loss(6,315)(5,943)
Retained earnings123,538128,052
Total stockholders’ equity208,536212,265
Total liabilities and stockholders’ equity$ 263,744$ 270,632
ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
 CEO
 WEBSITEanikatherapeutics.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES345

Anika Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Anika Therapeutics Inc? What does ANIK stand for in stocks?

ANIK is the stock ticker symbol of Anika Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anika Therapeutics Inc (ANIK)?

As of Thu Jun 13 2024, market cap of Anika Therapeutics Inc is 385.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers. The fair value of Anika Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anika Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anika Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ANIK is over valued or under valued. Whether Anika Therapeutics Inc is cheap or expensive depends on the assumptions which impact Anika Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIK.

What is Anika Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, ANIK's PE ratio (Price to Earnings) is -5.01 and Price to Sales (PS) ratio is 2.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anika Therapeutics Inc's stock?

In the past 10 years, Anika Therapeutics Inc has provided -0.055 (multiply by 100 for percentage) rate of return.